ALLK Allakos Inc.

71.33
+1.36  (+2%)
Previous Close 69.97
Open 69.71
Price To Book 22.72
Market Cap 3,453,265,408
Shares 48,412,525
Volume 325,982
Short Ratio
Av. Daily Volume 532,074
Stock charts supplied by TradingView

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 1 data May 7, 2019 noted a 78% median improvement in ocular symptoms
AK002
Severe Allergic Conjunctivitis
Phase 1 data released February 19, 2019.
AK002
Indolent Systemic Mastocytosis
Phase 2 additional data released February 11, 2019. 9% UAS7 complete responder rate.
AK002
Chronic Urticaria
Phase 2 top-line data met primary and secondary endpoints - August 5, 2019. Extension data due 1H 2020. Phase 3 trial to commence 1Q 2020.
AK002
Eosinophilic Gastritis